Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CREKA-GK8-QC is a smart, dual-targeted near-infrared (NIR-I) molecular imaging probe designed for the precise diagnosis and intraoperative fluorescence image-guided surgery of breast cancer. It combines a fibronectin-targeting peptide (CREKA) with an MMP-9-cleavable peptide sequence (GK8) and pairs them with a fluorescent dye (Cy5.5) and a fluorescence quencher (QSY21). This composition enables the probe to bind selectively to fibronectin in the tumor microenvironment and exhibit MMP-9-specific activatable fluorescence. The probe self-assembles into nanoparticles (~22 nm diameter), remaining quenched until encountering MMP-9, which cleaves the peptide and restores fluorescence, effectively highlighting tumors and micro-metastases for enhanced surgical guidance. Preclinical studies indicate strong tumor targeting, high imaging contrast, and negligible cytotoxicity[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CREKA-GK8-QC.